Routes of
administration Oral Legal status Investigational CAS Number 607742-69-8 Molar mass 353.44 g/mol | ATC code none Synonyms SB-742457, RVT-101 PubChem CID 11256720 | |
 | ||
Intepirdine (INN; developmental codes SB-742457, RVT-101) is a selective 5-HT6 receptor antagonist with potential cognition, memory, and learning-enhancing effects. It was under development by GlaxoSmithKline for the treatment of Alzheimer's disease and demonstrated some preliminary efficacy in phase II clinical trials; however, GSK chose not to continue development and sold the rights to Axovant Sciences in December 2014.
A phase 3 clinical trial for Alzheimer's is due to report in 2017.
It is also in a phase 2 trial for dementia with Lewy bodies.
References
Intepirdine Wikipedia(Text) CC BY-SA